Concert Pharmaceuticals (CNCE) is developing innovative medicines with deuterium chemistry (heavy hydrogen) to address the needs of patients with chronic diseases. That's over my pay grade but the charts are interesting. Let's check it out.
More from Investing
These recently downgraded names are displaying both quantitative and technical deterioration.
Do you formulate a strategy when you enter a trade, or do you just hope for good luck?
We started out with corrective action and economic concerns, but then the buyers jumped in. Here's what to watch now.